Loading...

Lexicon Pharmaceuticals

DB:LX31
Snowflake Description

High growth potential with mediocre balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
LX31
DB
$593M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The last earnings update was 36 days ago. More info.


Add to Portfolio Compare Print
  • Lexicon Pharmaceuticals has significant price volatility in the past 3 months.
LX31 Share Price and Events
7 Day Returns
-9%
DB:LX31
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-
DB:LX31
-10.2%
DE Biotechs
-6%
DE Market
LX31 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Lexicon Pharmaceuticals (LX31) -9% -26.2% -7.4% - -60.2% -36.6%
DE Biotechs -2.4% 1.8% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.2% 7.4% -6% 10.1% 15.4%
1 Year Return vs Industry and Market
  • No trading data on LX31.
  • No trading data on LX31.
Price Volatility
LX31
Industry
5yr Volatility vs Market

LX31 Value

 Is Lexicon Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Lexicon Pharmaceuticals is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Lexicon Pharmaceuticals has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Lexicon Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is €4.91.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Lexicon Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Lexicon Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:LX31 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.14
NasdaqGS:LXRX Share Price ** NasdaqGS (2019-04-18) in USD $5.58
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Lexicon Pharmaceuticals.

DB:LX31 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:LXRX Share Price ÷ EPS (both in USD)

= 5.58 ÷ -1.14

-4.9x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Lexicon Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Lexicon Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Lexicon Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:LX31 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.9x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
49.7%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Lexicon Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Lexicon Pharmaceuticals's assets?
Raw Data
DB:LX31 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $-0.25
NasdaqGS:LXRX Share Price * NasdaqGS (2019-04-18) in USD $5.58
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.84x
DB:LX31 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:LXRX Share Price ÷ Book Value per Share (both in USD)

= 5.58 ÷ -0.25

-22.38x

* Primary Listing of Lexicon Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Lexicon Pharmaceuticals has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.

Next steps:

  1. Take a look at Lexicon Pharmaceuticals's forecasted future earnings and revenues from industry analysts to understand how the company is expected to perform in the future against its competitors and the wider market.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Lexicon Pharmaceuticals's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Biotechs industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Lexicon Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Lexicon Pharmaceuticals has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

LX31 Future Performance

 How is Lexicon Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
49.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Lexicon Pharmaceuticals expected to grow at an attractive rate?
  • Lexicon Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Lexicon Pharmaceuticals's earnings growth is expected to exceed the Germany market average.
  • Lexicon Pharmaceuticals's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:LX31 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:LX31 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts 49.7%
DB:LX31 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts 31.9%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:LX31 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:LX31 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 393 210 3
2022-12-31 317 134 3
2021-12-31 264 175 3
2020-12-31 110 -55 -101 5
2019-12-31 110 18 -35 6
DB:LX31 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 63 -149 -121
2018-09-30 79 -155 -133
2018-06-30 99 -167 -136
2018-03-31 97 -147 -136
2017-12-31 92 -185 -123
2017-09-30 80 -200 -133
2017-06-30 81 -202 -138
2017-03-31 89 -217 -141
2016-12-31 79 -176 -131
2016-09-30 188 139 -22
2016-06-30 160 149 -22
2016-03-31 141 165 -11

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Lexicon Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Lexicon Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:LX31 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Lexicon Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:LX31 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 1.72 2.02 1.42 2.00
2022-12-31 1.08 1.16 1.00 2.00
2021-12-31
2020-12-31 -0.76 -0.31 -1.60 5.00
2019-12-31 -0.32 0.23 -0.95 5.00
DB:LX31 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.14
2018-09-30 -1.25
2018-06-30 -1.29
2018-03-31 -1.29
2017-12-31 -1.17
2017-09-30 -1.27
2017-06-30 -1.33
2017-03-31 -1.36
2016-12-31 -1.27
2016-09-30 -0.21
2016-06-30 -0.21
2016-03-31 -0.11

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Lexicon Pharmaceuticals will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Lexicon Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Lexicon Pharmaceuticals has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

LX31 Past Performance

  How has Lexicon Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Lexicon Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Lexicon Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Lexicon Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Lexicon Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Lexicon Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Lexicon Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:LX31 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 63.21 -120.55 63.75
2018-09-30 78.86 -132.67 63.33
2018-06-30 98.95 -135.88 64.47
2018-03-31 97.25 -136.23 66.19
2017-12-31 91.69 -122.99 66.09
2017-09-30 80.33 -133.09 64.04
2017-06-30 81.10 -138.38 59.58
2017-03-31 89.14 -141.44 49.52
2016-12-31 79.26 -131.45 43.16
2016-09-30 187.58 -22.26 35.53
2016-06-30 160.43 -21.53 28.64
2016-03-31 140.72 -11.49 26.53
2015-12-31 130.01 -4.68 23.84
2015-09-30 24.22 -94.37 21.38
2015-06-30 24.07 -99.58 20.61
2015-03-31 24.37 -97.54 19.46
2014-12-31 22.85 -100.29 19.41
2014-09-30 2.78 -114.78 18.84
2014-06-30 2.60 -105.94 18.93
2014-03-31 2.14 -108.99 18.45
2013-12-31 2.22 -104.13 17.12
2013-09-30 1.03 -111.59 17.63
2013-06-30 1.16 -109.47 17.31
2013-03-31 1.15 -106.32 16.80
2012-12-31 1.09 -110.21 17.04
2012-09-30 1.21 -119.18 17.13
2012-06-30 1.20 -115.75 16.79

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Lexicon Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Lexicon Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Lexicon Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Lexicon Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Lexicon Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

LX31 Health

 How is Lexicon Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Lexicon Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Lexicon Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Lexicon Pharmaceuticals's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Lexicon Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Lexicon Pharmaceuticals has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Lexicon Pharmaceuticals Company Filings, last reported 3 months ago.

DB:LX31 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 -26.41 245.00 160.05
2018-09-30 -29.40 244.95 187.30
2018-06-30 -5.07 245.09 209.69
2018-03-31 26.19 245.40 262.27
2017-12-31 68.27 245.67 310.79
2017-09-30 78.38 100.15 196.82
2017-06-30 106.31 100.54 231.19
2017-03-31 134.60 101.02 259.74
2016-12-31 157.40 101.45 346.50
2016-09-30 185.18 101.83 395.56
2016-06-30 217.33 102.20 429.37
2016-03-31 252.88 102.57 477.15
2015-12-31 285.85 102.94 521.35
2015-09-30 197.94 106.29 255.99
2015-06-30 231.47 106.76 282.05
2015-03-31 257.61 107.21 314.67
2014-12-31 284.02 107.67 338.91
2014-09-30 77.82 20.61 57.44
2014-06-30 116.67 21.04 78.61
2014-03-31 140.78 21.46 97.94
2013-12-31 170.16 21.88 129.13
2013-09-30 185.71 22.28 150.78
2013-06-30 215.08 22.68 174.95
2013-03-31 242.21 23.06 196.73
2012-12-31 266.68 23.45 223.21
2012-09-30 252.76 23.83 206.42
2012-06-30 244.90 24.19 231.08
  • Lexicon Pharmaceuticals has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Lexicon Pharmaceuticals's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Lexicon Pharmaceuticals has sufficient cash runway for 1.1 years based on current free cash flow.
  • Lexicon Pharmaceuticals has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 73% each year.
X
Financial health checks
We assess Lexicon Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Lexicon Pharmaceuticals has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

LX31 Dividends

 What is Lexicon Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Lexicon Pharmaceuticals dividends. Estimated to be 0% next year.
If you bought €2,000 of Lexicon Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Lexicon Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Lexicon Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:LX31 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:LX31 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Lexicon Pharmaceuticals has not reported any payouts.
  • Unable to verify if Lexicon Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Lexicon Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Lexicon Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Lexicon Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Lexicon Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Lexicon Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Lexicon Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

LX31 Management

 What is the CEO of Lexicon Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Lonnel Coats
COMPENSATION $3,123,433
AGE 53
TENURE AS CEO 4.8 years
CEO Bio

Mr. Lonnel Coats has been the Chief Executive Officer and President of Lexicon Pharmaceuticals, Inc., since July 7, 2014. Mr. Coats served as an Executive Vice President, President of Americas Region at Eisai Inc. He served as the Chief Executive Officer of Eisai Inc from June 18, 2010 to April 1, 2014 and President of Eisai Inc from 2004 to April 1, 2014 and served as its Vice President and Senior Vice President. He was Executive Officer at Eisai Inc from April 1, 2014 to June 2014. He served in a series of leadership positions at Eisai Inc. and Eisai Corporation of North America, U.S. subsidiaries of Tokyo-based Eisai Co., Ltd., from 1996 to June 2014. Mr. Coats also previously held a variety of sales and management positions at Janssen Pharmaceuticals, Inc., a division of Johnson & Johnson, from 1988 to 1996. Mr. Coats served as Chief Executive Officer and President of Eisai, Inc. until April 1, 2014. He served as Chief Operating Officer at Eisai Corporation of North America, Inc until June 2010 and President. He served as Executive Vice President at Eisai Co., Ltd. and its Senior Vice President since June 2010. He served as Vice President at Eisai Co., Ltd. until June 2010. He served as the Chief Operating Officer of Eisai Inc from 2004 to June 18, 2010. Mr. Coats has been a Director of Blueprint Medicines Corporation since February 4, 2016 and Lexicon Pharmaceuticals, Inc. since July 2014. Mr. Coats served as a Director of MGI Pharma, Inc. since January 2008. He serves as Member of Board of Governors at Hackensack University Medical Center. He holds a B.S. in Public Administration from Oakland University in Michigan. Eisai

CEO Compensation
  • Lonnel's compensation has increased whilst company is loss making.
  • Lonnel's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Lexicon Pharmaceuticals management team in years:

6.8
Average Tenure
58
Average Age
  • The average tenure for the Lexicon Pharmaceuticals management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Lonnel Coats

TITLE
President
COMPENSATION
$3M
AGE
53
TENURE
4.8 yrs

Jeffrey Wade

TITLE
Executive VP of Corporate & Administrative Affairs and CFO
COMPENSATION
$1M
AGE
53
TENURE
8.9 yrs

Pablo Lapuerta

TITLE
Executive VP & Chief Medical Officer
COMPENSATION
$1M
AGE
55
TENURE
4.2 yrs

Praveen Tyle

TITLE
Executive Vice President of Research & Development
COMPENSATION
$1M
AGE
58
TENURE
2.9 yrs

Alex Santini

TITLE
Executive VP & Chief Commercial Officer
COMPENSATION
$1M
AGE
59
TENURE
2.4 yrs

Robert Lefkowitz

TITLE
Consultant & Director
COMPENSATION
$96K
AGE
74
TENURE
16.1 yrs

James Tessmer

TITLE
Vice President of Finance & Accounting
COMPENSATION
$508K
AGE
58
TENURE
11.4 yrs

Kimberly Lee

TITLE
Head of Investor Relations & Corporate Strategy

Brian Crum

TITLE
Vice President

Chas Schultz

TITLE
Executive Director of Corporate Communications & Patient Advocacy
TENURE
18.3 yrs
Board of Directors Tenure

Average tenure and age of the Lexicon Pharmaceuticals board of directors in years:

11.7
Average Tenure
63
Average Age
  • The average tenure for the Lexicon Pharmaceuticals board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Ray Debbane

TITLE
Chairman of the Board
COMPENSATION
$80K
AGE
63
TENURE
7.2 yrs

Lonnel Coats

TITLE
President
COMPENSATION
$3M
AGE
53
TENURE
4.8 yrs

Sam Barker

TITLE
Independent Director
COMPENSATION
$69K
AGE
75
TENURE
19.1 yrs

Robert Lefkowitz

TITLE
Consultant & Director
COMPENSATION
$96K
AGE
74
TENURE
18.2 yrs

Alan Nies

TITLE
Chairman of Medical Advisory Board & Independent Director
COMPENSATION
$137K
AGE
80
TENURE
16.1 yrs

Frank Palantoni

TITLE
Independent Director
COMPENSATION
$69K
AGE
61
TENURE
14.4 yrs

Philippe Amouyal

TITLE
Independent Director
COMPENSATION
$64K
AGE
59
TENURE
11.7 yrs

Christopher Sobecki

TITLE
Independent Director
COMPENSATION
$60K
AGE
59
TENURE
11.7 yrs

Judith Swain

TITLE
Independent Director
COMPENSATION
$66K
AGE
69
TENURE
11.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
04. Jun 18 Buy The Invus Group, LLC Company 31. May 18 01. Jun 18 294,678 €10.47 €3,009,159
25. May 18 Buy Alexander Santini Individual 23. May 18 23. May 18 745 €8.36 €6,226
X
Management checks
We assess Lexicon Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Lexicon Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

LX31 News

Simply Wall St News

LX31 Company Info

Description

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase III clinical trials for the treatment of type 1 and type 2 diabetes; LX9211, which is in Phase Ib clinical development for the treatment of neuropathic pain; and LX2761 that is in Phase I clinical development for the treatment of diabetes. The company has strategic collaboration and license agreements with Sanofi; Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.

Details
Name: Lexicon Pharmaceuticals, Inc.
LX31
Exchange: DB
Founded: 1995
$527,293,245
106,271,927
Website: http://www.lexpharma.com
Address: Lexicon Pharmaceuticals, Inc.
8800 Technology Forest Place,
The Woodlands,
Texas, 77381,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS LXRX Common Shares Nasdaq Global Select US USD 07. Apr 2000
DB LX31 Common Shares Deutsche Boerse AG DE EUR 07. Apr 2000
MUN LX31 Common Shares Boerse Muenchen DE EUR 07. Apr 2000
Number of employees
Current staff
Staff numbers
202
Lexicon Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/20 20:46
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/03/25
Last earnings filing: 2019/03/15
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.